QIAGEN N.V. (QGEN)

NL0015001WM6 - Common Stock

43.45  +0.66 (+1.54%)

After market: 43.45 0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to QGEN. QGEN was compared to 60 industry peers in the Life Sciences Tools & Services industry. While QGEN has a great profitability rating, there are some minor concerns on its financial health. QGEN has a correct valuation and a medium growth rate.



7

1. Profitability

1.1 Basic Checks

In the past year QGEN was profitable.
QGEN had a positive operating cash flow in the past year.
Of the past 5 years QGEN 4 years were profitable.
Each year in the past 5 years QGEN had a positive operating cash flow.

1.2 Ratios

The Return On Assets of QGEN (5.58%) is better than 80.00% of its industry peers.
The Return On Equity of QGEN (8.96%) is better than 78.33% of its industry peers.
With a decent Return On Invested Capital value of 7.16%, QGEN is doing good in the industry, outperforming 78.33% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for QGEN is in line with the industry average of 9.12%.
Industry RankSector Rank
ROA 5.58%
ROE 8.96%
ROIC 7.16%
ROA(3y)6.88%
ROA(5y)5.2%
ROE(3y)12.58%
ROE(5y)9.79%
ROIC(3y)9.15%
ROIC(5y)8.32%

1.3 Margins

With an excellent Profit Margin value of 17.36%, QGEN belongs to the best of the industry, outperforming 88.33% of the companies in the same industry.
QGEN's Profit Margin has improved in the last couple of years.
QGEN has a Operating Margin of 22.65%. This is amongst the best in the industry. QGEN outperforms 91.67% of its industry peers.
QGEN's Operating Margin has improved in the last couple of years.
QGEN has a better Gross Margin (62.78%) than 90.00% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 22.65%
PM (TTM) 17.36%
GM 62.78%
OM growth 3Y-7.62%
OM growth 5Y2.99%
PM growth 3Y-3.3%
PM growth 5Y6.5%
GM growth 3Y-1.61%
GM growth 5Y-1.22%

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so QGEN is still creating some value.
The number of shares outstanding for QGEN has been reduced compared to 1 year ago.
The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
The debt/assets ratio for QGEN has been reduced compared to a year ago.

2.2 Solvency

QGEN has an Altman-Z score of 3.83. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of QGEN (3.83) is better than 65.00% of its industry peers.
The Debt to FCF ratio of QGEN is 5.09, which is a neutral value as it means it would take QGEN, 5.09 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.09, QGEN is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
QGEN has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
QGEN's Debt to Equity ratio of 0.24 is in line compared to the rest of the industry. QGEN outperforms 45.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 5.09
Altman-Z 3.83
ROIC/WACC0.86
WACC8.37%

2.3 Liquidity

QGEN has a Current Ratio of 1.99. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
QGEN has a worse Current ratio (1.99) than 71.67% of its industry peers.
QGEN has a Quick Ratio of 1.62. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
QGEN's Quick ratio of 1.62 is on the low side compared to the rest of the industry. QGEN is outperformed by 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.62

4

3. Growth

3.1 Past

The earnings per share for QGEN have decreased strongly by -10.68% in the last year.
QGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.58% yearly.
The Revenue has decreased by -8.23% in the past year.
The Revenue has been growing slightly by 5.53% on average over the past years.
EPS 1Y (TTM)-10.68%
EPS 3Y-0.51%
EPS 5Y9.58%
EPS growth Q2Q3.77%
Revenue 1Y (TTM)-8.23%
Revenue growth 3Y1.67%
Revenue growth 5Y5.53%
Revenue growth Q2Q2.24%

3.2 Future

QGEN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.85% yearly.
Based on estimates for the next years, QGEN will show a quite strong growth in Revenue. The Revenue will grow by 9.63% on average per year.
EPS Next Y2.99%
EPS Next 2Y5.8%
EPS Next 3Y8.21%
EPS Next 5Y6.85%
Revenue Next Year5%
Revenue Next 2Y6%
Revenue Next 3Y6.84%
Revenue Next 5Y9.63%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 20.50, which indicates a rather expensive current valuation of QGEN.
Compared to the rest of the industry, the Price/Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 96.67% of the companies listed in the same industry.
QGEN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.31.
The Price/Forward Earnings ratio is 19.93, which indicates a rather expensive current valuation of QGEN.
QGEN's Price/Forward Earnings ratio is rather cheap when compared to the industry. QGEN is cheaper than 96.67% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.87. QGEN is around the same levels.
Industry RankSector Rank
PE 20.5
Fwd PE 19.93

4.2 Price Multiples

95.00% of the companies in the same industry are more expensive than QGEN, based on the Enterprise Value to EBITDA ratio.
QGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. QGEN is cheaper than 81.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 32.42
EV/EBITDA 14.88

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)6.84
PEG (5Y)2.14
EPS Next 2Y5.8%
EPS Next 3Y8.21%

3

5. Dividend

5.1 Amount

QGEN has a Yearly Dividend Yield of 3.04%. Purely for dividend investing, there may be better candidates out there.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.64. QGEN pays more dividend than 100.00% of the companies in the same industry.
QGEN's Dividend Yield is a higher than the S&P500 average which is at 2.44.
Industry RankSector Rank
Dividend Yield 3.04%

5.2 History

QGEN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y5.8%
EPS Next 3Y8.21%

QIAGEN N.V.

NYSE:QGEN (3/1/2024, 7:04:00 PM)

After market: 43.45 0 (0%)

43.45

+0.66 (+1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.62B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 3.04%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 20.5
Fwd PE 19.93
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)6.84
PEG (5Y)2.14
Profitability
Industry RankSector Rank
ROA 5.58%
ROE 8.96%
ROCE
ROIC
ROICexc
ROICexgc
OM 22.65%
PM (TTM) 17.36%
GM 62.78%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.99
Quick Ratio 1.62
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-10.68%
EPS 3Y-0.51%
EPS 5Y
EPS growth Q2Q
EPS Next Y2.99%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.23%
Revenue growth 3Y1.67%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y